Fungal Peritonitis -Current Status 1998

Lo, Wai-Kei; Chan, Tak-Mao; Lui, Sing-Leung; Li, Fu-Keung; Cheng, Ignatius K.P.

doi:10.1177/089686089901902s48

Cited by 22 publications

(29 citation statements)

References 30 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Candida species account for most cases of fungal peritonitis; C. albicans, C. parapsilosis, and C. tropicalis generally predominate. [1][2][3] These species are usually susceptible to triazole-antifungals. The emergence of resistant species, however, is possible with the frequent use of these agents, especially in major medical centers.…”

Section: Discussionmentioning

confidence: 99%

“…Therapy for fungal peritonitis includes both antifungal agents and repair of the underlying pathological conditions, including the removal of the implicated catheter in CAPD-related cases, unless a prompt response is achieved with medical therapy alone. 1,2 The exact role of antifungal agents after surgical intervention in secondary peritonitis remains to be established. Treatment is generally indicated in cases with heavy growth of Candida or increasing colony counts with sequential peritoneal cultures.…”

Section: Discussionmentioning

confidence: 99%

“…Fungal peritonitis is an uncommon but serious complication of peritoneal dialysis and intra-abdominal pathological conditions. [1][2][3][4][5][6][7] It is associated with high morbidity and mortality. Over the last 2 decades the proportion of bloodstream infections caused by nonalbicans triazole-resistant Candida species has increased.…”

Section: Introductionmentioning

confidence: 99%

See 2 more Smart Citations

Fungal peritonitis at a tertiary care community teaching hospital: epidemiology, treatments, and outcome over a 3 year timespan*

Almoujahed

Riederer

Baran

2004

Mycoses

View full text Add to dashboard Cite

Fungal species isolated from the peritoneal cavity over a 3-year period were equally divided among dialysis and intra-abdominal sources and demonstrated that triazole antifungal susceptible species predominated. The evolution toward triazole-resistant species/strains noted in bloodstream infections has not yet developed in fungal peritonitis. A trend toward non-albicans species in continuous ambulatory peritoneal dialysis (CAPD) cases, however, requires careful monitoring. ZusammenfassungPilzisolate aus dem Peritoneum ü ber einen Dreijahreszeitraum waren gleichmäßig auf Dialyse-und intraabdominale Herkunft verteilt. Triazo-sensible Stämme, wie bei Blutkulturisolaten beobachtet, fanden sich unter Peritonealisolaten nicht. Allerdings verlangt der Trend zu vermehrten non-albicans-Arten bei CAPD erhöhte Sorgfalt im Therapiemonitoring.

show abstract

Section: Discussionmentioning

confidence: 99%

Section: Discussionmentioning

confidence: 99%

See 1 more Smart Citation

Fungal peritonitis at a tertiary care community teaching hospital: epidemiology, treatments, and outcome over a 3 year timespan*

Almoujahed

Riederer

Baran

2004

Mycoses

View full text Add to dashboard Cite

show abstract

“…The treatment for fungal peritonitis includes fluconazole, amphotericin B and flucytosine, alone or as combination therapy, based on fungal susceptibilities (4). However, these conventional antifungal regimens are disappointing, because it usually leads to removal of catheters or may transfer patients to hemodialysis (5).…”

Section: Introductionmentioning

confidence: 99%

Fungal peritonitis in continuous ambulatory peritoneal dialysis patients; a study from South of India

Suryanarayana¹,

Elumalai²,

Ramanathan³

et al. 2018

Immunopathol Persa

View full text Add to dashboard Cite

Introduction: Fungal peritonitis is a potential life-threatening complication for patients undergoing continuous ambulatory peritoneal dialysis (CAPD). Objectives: To assess the incidence and outcome of fungal peritonitis in CAPD patients. Patients and Methods: Dialysis records of all end-stage renal disease patients initiated on CAPD treatment were reviewed retrospectively. The study was conducted during January 2010 to December 2016. Mann-Whitney U test was applied for data analysis. Results: Out of 265 dialysis patients, a total of 36 fungal peritonitis were recorded. The incidence rate of fungal peritonitis was 13.6%. The majority of cases was affected by Candida albicans was 41.6%. Moreover, the major cause of end-stage renal disease (ESRD) in our study was diabetic nephropathy in 38.8% of cases. Conclusion: In this study, we found initiation of antifungal therapy and early removal of catheter reduced the mortality rate of fungal peritonitis in CAPD patients. AbstractCitation: Suryanarayana RY, Ramanathan G, Elumalai R, Matcha J. Fungal peritonitis in continuous ambulatory peritoneal dialysis patients; a study from South of India. Immunopathol Persa. 2018;4(2):e15.

show abstract

“…A large scale, prospective, randomized controlled trial is needed to further examine this issue. F ungal peritonitis (FP) is an important complication of peritoneal dialysis (PD), accounting for up to 15% of peritonitis (1). It is associated with significant mortality and a high technique failure rate, with up to 67% of patients requiring conversion to hemodialysis (1,2).…”

mentioning

confidence: 99%

Prevention of Fungal Peritonitis with Nystatin Prophylaxis in Patients Receiving CAPD

Wong

Tong

et al. 2007

Perit Dial Int

View full text Add to dashboard Cite

Objective Fungal peritonitis (FP) is a serious complication of continuous ambulatory peritoneal dialysis (CAPD), being associated with significant morbidity and mortality. The role of nystatin prophylaxis during antibiotic therapy in the prevention of FP remains controversial, especially in programs with a modest or low baseline FP rate. The aim of the present study was to evaluate the effect of nystatin prophylaxis on the occurrence of FP in programs with a relatively modest baseline FP rate. Patients and Methods Incident and prevalent patients receiving CAPD between April 1995 and April 2005 at our center were included and divided into 2 groups. The control group included 320 patients (total follow-up 8875 patient-months) being treated without nystatin before October 1999; the nystatin group included 481 patients (total follow-up 13725 patient-months) being treated after October 1999. Nystatin tablets (500000 units, 4 times per day) were given orally during whatever use of antibiotics to cover the whole course of antibiotic therapy. Occurrence of FP and antibiotic-related FP (AR-FP) in patients with and without nystatin prophylaxis was compared. Results The two groups were of similar age but the nystatin group had a significantly higher percentage of diabetics. In addition, the nystatin group had a higher proportion of patients using disconnecting twin-bag exchange systems and had a significantly lower peritonitis rate compared with the control. There were 13 and 14 episodes of FP in the nystatin and control groups respectively. The fungal peritonitis rate of the nystatin group was slightly lower than that of the control group (0.011 vs 0.019 per patient-year) but it did not reach statistical significance. There was, however, a significant decrease in the incidence and proportion of AR-FP in the nystatin group compared with the control group, which persisted even after adjustment for the peritonitis rate. Kaplan–Meier analysis further demonstrated significantly better AR-FP-free survival in the nystatin group compared with the control group. No significant side effects were observed for nystatin. Subgroup analyses in patients of the 2 different connecting systems revealed a similar but nonsignificant trend toward reduction of AR-FP in patients given nystatin prophylaxis. Conclusion Oral nystatin prophylaxis might prevent the occurrence of AR-FP in CAPD patients, resulting in a trend toward reduction in the incidence of FP even in programs with a modest baseline FP rate. A large scale, prospective, randomized controlled trial is needed to further examine this issue.

show abstract

Fungal Peritonitis -Current Status 1998

Cited by 22 publications

References 30 publications

Fungal peritonitis at a tertiary care community teaching hospital: epidemiology, treatments, and outcome over a 3 year timespan*

Fungal peritonitis at a tertiary care community teaching hospital: epidemiology, treatments, and outcome over a 3 year timespan*

Fungal peritonitis in continuous ambulatory peritoneal dialysis patients; a study from South of India

Prevention of Fungal Peritonitis with Nystatin Prophylaxis in Patients Receiving CAPD

Contact Info

Product

Resources

About